Abstract
Background Group A Streptococcus (GAS) is a major human pathogen and an important cause of maternal and neonatal sepsis.
Methods We performed a posthoc analysis of a double-blind, placebo-controlled randomized-trial (ratio 1:1) carried out in The Gambia to determine the impact of one oral dose (2g) of intra-partum azithromycin on maternal and neonatal GAS carriage. Breast milk, nasopharyngeal and vaginal swabs were collected at different time points during 4 weeks post-treatment. All samples were processed using conventional microbiology techniques. Whole genome sequencing (WGS) of GAS isolates was performed by Illumina MiSeq platform.
Results We randomized 829 mothers who delivered 843 babies. GAS carriage in mothers in the azithromycin arm was lower in breast milk (0.28% vs 2.48%, Prevalence Ratio (PR)=0.11, 95% CI 0.01-0.90) and the nasopharynx (0.28% vs 1.93%, PR=0.15, 95% CI 0.02-1.19), but not in the vaginal tract (1.99% vs 1.93%, PR=1.03, 95% CI 0.37-2.91). Among neonates, GAS carriage in the nasopharynx was slightly lower in the azithromycin arm (0.57% vs 1.91%, PR=0.30, 95% CI 0.06-1.42). Prevalence of azithromycin-resistant GAS was similar in both arms, except for a higher prevalence in the vaginal tract among women in the azithromycin arm (1.99% vs 0.28%, PR=7.24, 95% CI 0.87-56.92). WGS revealed ten of the 45 GAS isolates (22.2%) were Streptococcus dysgalactiae subspecies equisimilis expressing Lancefield group A carbohydrate (SDSE(A)). All SDSE(A) isolates were azithromycin-resistant, harbouring macrolide resistant genes msrD and mefA.
Conclusions Oral intra-partum azithromycin reduced prevalence of GAS carriage among mothers and neonates. Azithromycin-resistant SDSE(A) carriage was observed among participants treated with azithromycin.
Short Summary Group A streptococcus (GAS) is an important cause of sepsis. One oral dose (2g) of intra-partum azithromycin reduced maternal and neonatal GAS carriage. However, azithromycin-resistant Streptococcus dysgalactiae subspecies equisimilis expressing Lancefield group A carbohydrate was detected in women receiving azithromycin.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT01800942
Funding Statement
The MRC Unit in The Gambia at LSHTM receives core funding from the MRC UK. The trial was jointly funded by the MRC UK and the UK Department for International Development (DFID) under the MRC/DFID Concordat agreement (reference number MR/J010391/1). The WGS was funded by a HEFCE/ODA grant from The University of Sheffield (155123). TdS is funded by a Wellcome Trust Intermediate Clinical Fellowship (110058/Z/15/Z). CET is a Royal Society & Wellcome Trust Sir Henry Dale Fellow (208765/Z/17/Z).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for the main trial was obtained from the Joint MRC Gambia Government Ethics Committee. Ethical approval was given by LSHTM for the secondary data analysis.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Email: ijcox{at}mrc.gm
Email: a.keeley{at}sheffield.ac.uk
Email: ambojang{at}mrc.gm
Email: bcamara{at}mrc.gm
Email: edjallow{at}mrc.gm
Email: esenghore{at}mrc.gm
Email: coluwalana{at}mrc.gm
Email: s.bah{at}sheffield.ac.uk
Email: c.e.turner{at}sheffield.ac.uk
Email: aksesay{at}mrc.gm
Email: udalessandro{at}mrc.gm
Email: christian.bottomley{at}lshtm.ac.uk
Email: t.desilva{at}sheffield.ac.uk
Email: aroca{at}mrc.gm
Data Availability
Access to data should be approved by the internal MRCG at the LSHTM committee (Scientific Coordinating Committee) which meets on monthly bases. Requests should be submitted to the Government department.